Long Term Outcomes in β Thalassemia Major - Comparing Late Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation and Standard Supportive Care

Official Title: Long Term Outcomes in β Thalassemia Major - Comparing Late Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation and Standard Supportive Care

The hypothesis is that patients who had beta thalassemia who have undergone a hematopoietic stem cell transplant (HSCT) and are >1 year post-HSCT will have less long term comorbidities and a higher quality of life (QOL) as compared to those with beta thalassemia who are maintained on supportive care.

ClinicalTrials.gov ID: NCT02307786

Principal Investigator: Chaudhury, Sonali, MD

Study Type: Observational

Currently Recruiting Patients: Yes

Contact Information:

Colleen E Rosen, RN, BS; Tennyson Mun, BA

312.227.4870; 312.227.4871

Specialties & Conditions

Patients & Visitors

Plan Your Visit

While You're Here

After Your Visit

Research Innovation

Long Term Outcomes in β Thalassemia Major - Comparing Late Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation and Standard Supportive Care

Official Title: Long Term Outcomes in β Thalassemia Major - Comparing Late Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation and Standard Supportive Care

Contact Information:

Find

Get in Touch

Get to Know Us

For Healthcare Professionals